Literature DB >> 2403998

What constitutes an adequate antidepressant trial for fluoxetine?

E Schweizer1, K Rickels, J D Amsterdam, I Fox, G Puzzuoli, C Weise.   

Abstract

One hundred and eight patients with major depression were treated with fluoxetine 20 mg/day for 3 weeks. Patients who failed to respond to this open-label treatment were randomly assigned either to receive fluoxetine 60 mg/day for 5 weeks or to continue treatment with fluoxetine 20 mg/day for an additional 5 weeks. Both treatment groups demonstrated a statistically significant reduction in depressive symptoms, indicating that continued treatment with low-dose fluoxetine may be as effective as an increase in dose in achieving a favorable clinical outcome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403998

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

Review 1.  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Authors:  M J Burke; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

2.  When common clinical practice meets evidence-based medicine.

Authors:  David Feifel
Journal:  Psychiatry (Edgmont)       Date:  2006-12

Review 3.  Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review.

Authors:  Mazda Adli; Christopher Baethge; Andreas Heinz; Nicolas Langlitz; Michael Bauer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04-29       Impact factor: 5.760

4.  Dose-response relationship of recent antidepressants in the short-term treatment of depression.

Authors:  Patricia Berney
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

5.  Pharmacological interventions for treatment-resistant depression in adults.

Authors:  Philippa Davies; Sharea Ijaz; Catherine J Williams; David Kessler; Glyn Lewis; Nicola Wiles
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17

Review 6.  Fluoxetine for adults who are overweight or obese.

Authors:  Aurora E Serralde-Zúñiga; Alejandro G Gonzalez Garay; Yanelli Rodríguez-Carmona; Guillermo Melendez
Journal:  Cochrane Database Syst Rev       Date:  2019-10-15

7.  Evidence-based, pharmacological treatment guideline for depression in Korea, revised edition.

Authors:  Eunsoo Won; Seon-Cheol Park; Kyu-Man Han; Seung-Hwan Sung; Hwa-Young Lee; Jong-Woo Paik; Hong Jin Jeon; Moon-Soo Lee; Se-Hoon Shim; Young-Hoon Ko; Kang-Joon Lee; Changsu Han; Byung-Joo Ham; Joonho Choi; Tae-Yeon Hwang; Kang-Seob Oh; Sang-Woo Hahn; Yong-Chon Park; Min-Soo Lee
Journal:  J Korean Med Sci       Date:  2014-04-01       Impact factor: 2.153

8.  ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis.

Authors:  Ching-Hua Lin; Chun-Jen Huang; Cheng-Chung Chen
Journal:  Int J Neuropsychopharmacol       Date:  2018-01-01       Impact factor: 5.176

9.  Use of Fluoxetine to Reduce Weight in Adults with Overweight or Obesity: Abridged Republication of the Cochrane Systematic Review.

Authors:  Aurora E Serralde-Zuñiga; Alejandro G González-Garay; Yanelli Rodríguez-Carmona; Guillermo Meléndez-Mier
Journal:  Obes Facts       Date:  2022-06-02       Impact factor: 4.807

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.